Symbols / VANI $1.11 +2.78% Vivani Medical, Inc.
VANI Chart
About
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease and medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in clinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature and subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant for metabolic diseases in cats. The company is headquartered in Alameda, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 93.96M |
| Enterprise Value | 94.04M | Income | -26.61M | Sales | — |
| Book/sh | 0.21 | Cash/sh | 0.19 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -3.17 | PEG | — |
| P/S | — | P/B | 5.39 | P/C | — |
| EV/EBITDA | -3.47 | EV/Sales | — | Quick Ratio | 2.56 |
| Current Ratio | 2.71 | Debt/Eq | 119.87 | LT Debt/Eq | — |
| EPS (ttm) | -0.43 | EPS next Y | -0.35 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-05-13 | ROA | -42.55% |
| ROE | -159.62% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 84.65M |
| Shs Float | 38.86M | Short Float | 0.56% | Short Ratio | 1.66 |
| Short Interest | — | 52W High | 1.92 | 52W Low | 0.92 |
| Beta | 3.37 | Avg Volume | 322.13K | Volume | 28.76K |
| Target Price | $4.83 | Recom | Strong_buy | Prev Close | $1.08 |
| Price | $1.11 | Change | 2.78% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-31 | main | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-09-02 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-05-19 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-04-16 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-04-04 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-03-26 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-03-13 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2024-11-07 | init | HC Wainwright & Co. | — → Buy | $3 |
| 2022-12-05 | init | ThinkEquity | — → Buy | $7 |
- Vivani Medical (VANI) Upgraded to Buy: What Does It Mean for the Stock? - finance.yahoo.com Fri, 03 Apr 2026 16
- New Analyst Forecast: $VANI Given $3.5 Price Target - quiverquant.com Wed, 01 Apr 2026 06
- Vivani Medical (VANI) Receives Buy Rating Upgrade: What Are the Implications for the Stock? - Bitget Fri, 03 Apr 2026 17
- HC Wainwright Lifts Earnings Estimates for Vivani Medical - MarketBeat Fri, 03 Apr 2026 11
- Single semaglutide implant showed >20% weight loss for a year - stocktitan.net hu, 26 Mar 2026 07
- Vivani medical director Williams buys shares worth $1.68 million - Investing.com Mon, 16 Mar 2026 07
- Vivani Medical: Q4 Earnings Snapshot - KVUE hu, 26 Mar 2026 20
- VIVANI MEDICAL ($VANI) Releases Q4 2025 Earnings, Stock Rises - quiverquant.com hu, 26 Mar 2026 07
- Vivani Medical (VANI) price target increased by 10.00% to 5.61 - MSN Sat, 28 Mar 2026 10
- Vivani Medical, Inc. (NASDAQ:VANI) insiders have had a fantastic week as stock increased 17%, and they haven't stopped buying - simplywall.st Fri, 23 Jan 2026 08
- Vivani Medical price target lowered to $3.50 from $4 at H.C. Wainwright - finance.yahoo.com Wed, 01 Apr 2026 15
- Vivani Medical (NASDAQ:VANI) Issues Quarterly Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat hu, 26 Mar 2026 21
- Vivani chair backs $4.5M raise for long-acting drug implants - stocktitan.net Sun, 25 Jan 2026 08
- Williams Gregg buys Vivani Medical (VANI) shares for $1.99m - Investing.com Wed, 28 Jan 2026 08
- Short Interest in Vivani Medical, Inc. (NASDAQ:VANI) Decreases By 25.4% - MarketBeat Sat, 14 Mar 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
27.56
+11.67%
|
24.68
-8.49%
|
26.96
+26.95%
|
21.24
|
| Research And Development |
|
18.13
+15.12%
|
15.74
-7.21%
|
16.97
+19.75%
|
14.17
|
| Selling General And Administration |
|
9.43
+5.58%
|
8.93
-10.65%
|
10.00
+41.36%
|
7.07
|
| General And Administrative Expense |
|
9.43
+5.58%
|
8.93
-10.65%
|
10.00
+41.36%
|
7.07
|
| Other Gand A |
|
9.43
+5.58%
|
8.93
-10.65%
|
10.00
+41.36%
|
7.07
|
| Total Expenses |
|
27.56
+11.67%
|
24.68
-8.49%
|
26.96
+26.95%
|
21.24
|
| Operating Income |
|
-27.56
-11.67%
|
-24.68
+8.49%
|
-26.96
-26.95%
|
-21.24
|
| Total Operating Income As Reported |
|
-27.56
-11.67%
|
-24.68
+8.49%
|
-26.96
-26.95%
|
-21.24
|
| EBITDA |
|
-27.13
-11.76%
|
-24.28
+8.76%
|
-26.61
-27.56%
|
-20.86
|
| Normalized EBITDA |
|
-27.13
-11.76%
|
-24.28
+8.76%
|
-26.61
-27.56%
|
-20.86
|
| Reconciled Depreciation |
|
0.42
+6.00%
|
0.40
+12.04%
|
0.36
-6.30%
|
0.38
|
| EBIT |
|
-27.56
-11.67%
|
-24.68
+8.49%
|
-26.96
-26.95%
|
-21.24
|
| Total Unusual Items |
|
—
|
—
|
—
|
6.88
|
| Total Unusual Items Excluding Goodwill |
|
—
|
—
|
—
|
6.88
|
| Special Income Charges |
|
—
|
—
|
—
|
6.88
|
| Other Special Charges |
|
—
|
—
|
—
|
—
|
| Restructuring And Mergern Acquisition |
|
—
|
—
|
—
|
-6.88
|
| Net Income |
|
-26.61
-13.30%
|
-23.49
+8.44%
|
-25.65
-84.69%
|
-13.89
|
| Pretax Income |
|
-26.61
-13.30%
|
-23.49
+8.44%
|
-25.65
-84.69%
|
-13.89
|
| Other Income Expense |
|
0.95
-20.49%
|
1.19
-9.29%
|
1.31
-82.14%
|
7.35
|
| Other Non Operating Income Expenses |
|
0.95
-20.49%
|
1.19
-9.29%
|
1.31
-82.14%
|
7.35
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-26.61
-13.30%
|
-23.49
+8.44%
|
-25.65
-84.69%
|
-13.89
|
| Net Income From Continuing Operation Net Minority Interest |
|
-26.61
-13.30%
|
-23.49
+8.44%
|
-25.65
-84.69%
|
-13.89
|
| Net Income From Continuing And Discontinued Operation |
|
-26.61
-13.30%
|
-23.49
+8.44%
|
-25.65
-84.69%
|
-13.89
|
| Net Income Continuous Operations |
|
-26.61
-13.30%
|
-23.49
+8.44%
|
-25.65
-84.69%
|
-13.89
|
| Normalized Income |
|
-26.61
-13.30%
|
-23.49
+8.44%
|
-25.65
-84.69%
|
-13.89
|
| Net Income Common Stockholders |
|
-26.61
-13.30%
|
-23.49
+8.44%
|
-25.65
-84.69%
|
-13.89
|
| Diluted EPS |
|
-0.43
+0.00%
|
-0.43
+14.00%
|
-0.50
-38.89%
|
-0.36
|
| Basic EPS |
|
-0.43
+0.00%
|
-0.43
+14.00%
|
-0.50
-38.89%
|
-0.36
|
| Basic Average Shares |
|
62.39
+13.47%
|
54.98
+8.12%
|
50.85
+32.98%
|
38.24
|
| Diluted Average Shares |
|
62.39
+13.47%
|
54.98
+8.12%
|
50.85
+32.98%
|
38.24
|
| Diluted NI Availto Com Stockholders |
|
-26.61
-13.30%
|
-23.49
+8.44%
|
-25.65
-84.69%
|
-13.89
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
39.39
-5.22%
|
41.56
-9.25%
|
45.80
-10.43%
|
51.13
|
| Current Assets |
|
17.90
-12.44%
|
20.44
-11.36%
|
23.06
-51.48%
|
47.53
|
| Cash Cash Equivalents And Short Term Investments |
|
16.23
-11.55%
|
18.35
-11.15%
|
20.65
-54.18%
|
45.08
|
| Cash And Cash Equivalents |
|
16.23
-11.55%
|
18.35
-11.15%
|
20.65
-54.18%
|
45.08
|
| Receivables |
|
0.65
+158.50%
|
0.25
|
0.00
|
—
|
| Taxes Receivable |
|
0.65
+158.50%
|
0.25
|
0.00
|
—
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Other Current Assets |
|
1.01
-44.91%
|
1.84
-23.71%
|
2.41
-1.79%
|
2.45
|
| Total Non Current Assets |
|
21.50
+1.78%
|
21.12
-7.11%
|
22.73
+531.18%
|
3.60
|
| Net PPE |
|
20.11
+2.34%
|
19.65
-7.94%
|
21.34
+988.48%
|
1.96
|
| Gross PPE |
|
23.16
+3.91%
|
22.29
-6.29%
|
23.79
+444.08%
|
4.37
|
| Accumulated Depreciation |
|
-3.05
-15.64%
|
-2.64
-8.15%
|
-2.44
-1.29%
|
-2.41
|
| Properties |
|
—
|
—
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
0.41
+3.27%
|
0.40
+9.97%
|
0.36
+491.80%
|
0.06
|
| Construction In Progress |
|
1.36
|
0.00
-100.00%
|
0.30
|
0.00
|
| Other Properties |
|
21.39
-2.30%
|
21.89
-5.33%
|
23.13
+437.96%
|
4.30
|
| Leases |
|
—
|
—
|
0.00
-100.00%
|
0.01
|
| Non Current Prepaid Assets |
|
0.05
-63.36%
|
0.13
+151.92%
|
0.05
-81.09%
|
0.28
|
| Other Non Current Assets |
|
1.34
+0.00%
|
1.34
-3.74%
|
1.39
+1.76%
|
1.37
|
| Total Liabilities Net Minority Interest |
|
23.66
-1.20%
|
23.95
-4.33%
|
25.04
+266.99%
|
6.82
|
| Current Liabilities |
|
6.60
+10.29%
|
5.99
+4.60%
|
5.72
-16.11%
|
6.82
|
| Payables And Accrued Expenses |
|
4.44
+3.45%
|
4.29
+8.90%
|
3.94
-24.30%
|
5.21
|
| Payables |
|
1.03
+26.32%
|
0.82
+50.74%
|
0.54
-53.95%
|
1.18
|
| Accounts Payable |
|
1.03
+26.32%
|
0.82
+50.74%
|
0.54
-53.95%
|
1.18
|
| Current Accrued Expenses |
|
3.41
-1.93%
|
3.48
+2.23%
|
3.40
-15.65%
|
4.03
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.36
+6.41%
|
0.34
-13.38%
|
0.40
-39.73%
|
0.66
|
| Current Debt And Capital Lease Obligation |
|
1.79
+33.09%
|
1.35
-2.53%
|
1.38
+44.82%
|
0.95
|
| Current Capital Lease Obligation |
|
1.79
+33.09%
|
1.35
-2.53%
|
1.38
+44.82%
|
0.95
|
| Total Non Current Liabilities Net Minority Interest |
|
17.06
-5.03%
|
17.96
-6.98%
|
19.31
|
0.00
|
| Long Term Debt And Capital Lease Obligation |
|
17.06
-5.03%
|
17.96
-6.98%
|
19.31
|
0.00
|
| Long Term Capital Lease Obligation |
|
17.06
-5.03%
|
17.96
-6.98%
|
19.31
|
0.00
|
| Stockholders Equity |
|
15.73
-10.68%
|
17.61
-15.18%
|
20.76
-53.14%
|
44.31
|
| Common Stock Equity |
|
15.73
-10.68%
|
17.61
-15.18%
|
20.76
-53.14%
|
44.31
|
| Capital Stock |
|
0.01
+33.33%
|
0.01
+20.00%
|
0.01
+0.00%
|
0.01
|
| Common Stock |
|
0.01
+33.33%
|
0.01
+20.00%
|
0.01
+0.00%
|
0.01
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
76.43
+29.03%
|
59.23
+16.08%
|
51.03
+0.58%
|
50.74
|
| Ordinary Shares Number |
|
76.43
+29.03%
|
59.23
+16.08%
|
51.03
+0.58%
|
50.74
|
| Additional Paid In Capital |
|
164.22
+17.74%
|
139.48
+17.16%
|
119.05
+1.71%
|
117.05
|
| Retained Earnings |
|
-148.53
-21.82%
|
-121.92
-23.86%
|
-98.44
-35.24%
|
-72.79
|
| Gains Losses Not Affecting Retained Earnings |
|
0.03
-37.50%
|
0.05
-65.71%
|
0.14
+300.00%
|
0.04
|
| Other Equity Adjustments |
|
0.03
-37.50%
|
0.05
-65.71%
|
0.14
+300.00%
|
0.04
|
| Total Equity Gross Minority Interest |
|
15.73
-10.68%
|
17.61
-15.18%
|
20.76
-53.14%
|
44.31
|
| Total Capitalization |
|
15.73
-10.68%
|
17.61
-15.18%
|
20.76
-53.14%
|
44.31
|
| Working Capital |
|
11.30
-21.86%
|
14.46
-16.63%
|
17.34
-57.40%
|
40.71
|
| Invested Capital |
|
15.73
-10.68%
|
17.61
-15.18%
|
20.76
-53.14%
|
44.31
|
| Total Debt |
|
18.86
-2.37%
|
19.31
-6.68%
|
20.70
+2067.12%
|
0.95
|
| Capital Lease Obligations |
|
18.86
-2.37%
|
19.31
-6.68%
|
20.70
+2067.12%
|
0.95
|
| Net Tangible Assets |
|
15.73
-10.68%
|
17.61
-15.18%
|
20.76
-53.14%
|
44.31
|
| Tangible Book Value |
|
15.73
-10.68%
|
17.61
-15.18%
|
20.76
-53.14%
|
44.31
|
| Line Of Credit |
|
—
|
—
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-24.32
-17.00%
|
-20.79
+12.29%
|
-23.70
-26.15%
|
-18.79
|
| Cash Flow From Continuing Operating Activities |
|
-24.32
-17.00%
|
-20.79
+12.29%
|
-23.70
-26.15%
|
-18.79
|
| Net Income From Continuing Operations |
|
-26.61
-13.30%
|
-23.49
+8.44%
|
-25.65
-84.69%
|
-13.89
|
| Depreciation Amortization Depletion |
|
0.42
+6.00%
|
0.40
+12.04%
|
0.36
-6.30%
|
0.38
|
| Depreciation And Amortization |
|
0.42
+6.00%
|
0.40
+12.04%
|
0.36
-6.30%
|
0.38
|
| Other Non Cash Items |
|
0.27
-2.54%
|
0.28
-69.47%
|
0.90
+113.08%
|
-6.91
|
| Stock Based Compensation |
|
1.48
-7.83%
|
1.61
-13.63%
|
1.86
+43.83%
|
1.30
|
| Asset Impairment Charge |
|
0.00
-100.00%
|
0.06
-50.41%
|
0.12
|
—
|
| Operating Gains Losses |
|
-0.12
|
—
|
0.12
|
—
|
| Net Foreign Currency Exchange Gain Loss |
|
-0.12
|
0.00
|
—
|
—
|
| Gain Loss On Sale Of PPE |
|
—
|
—
|
0.12
|
0.00
|
| Change In Working Capital |
|
0.23
-35.31%
|
0.35
+127.38%
|
-1.29
-482.54%
|
0.34
|
| Change In Receivables |
|
-0.40
-58.50%
|
-0.25
|
0.00
|
—
|
| Change In Prepaid Assets |
|
0.91
+84.93%
|
0.49
+85.98%
|
0.26
+155.46%
|
-0.48
|
| Change In Payables And Accrued Expense |
|
-0.28
-339.66%
|
0.12
+107.45%
|
-1.56
-291.28%
|
0.81
|
| Change In Accrued Expense |
|
-0.06
+57.58%
|
-0.13
+86.18%
|
-0.95
-134.66%
|
2.75
|
| Change In Payable |
|
-0.22
-189.52%
|
0.25
+141.20%
|
-0.60
+68.99%
|
-1.94
|
| Change In Account Payable |
|
-0.22
-189.52%
|
0.25
+141.20%
|
-0.60
+68.99%
|
-1.94
|
| Change In Other Working Capital |
|
—
|
—
|
—
|
0.20
|
| Change In Other Current Liabilities |
|
—
|
—
|
—
|
—
|
| Investing Cash Flow |
|
-1.17
-110.97%
|
-0.56
+37.32%
|
-0.89
-162.43%
|
-0.34
|
| Cash Flow From Continuing Investing Activities |
|
-1.17
-110.97%
|
-0.56
+37.32%
|
-0.89
-162.43%
|
-0.34
|
| Net PPE Purchase And Sale |
|
-1.17
-110.97%
|
-0.56
+37.32%
|
-0.89
-162.43%
|
-0.34
|
| Purchase Of PPE |
|
-1.17
-110.97%
|
-0.56
+37.32%
|
-0.89
-162.43%
|
-0.34
|
| Capital Expenditure |
|
-1.17
-110.97%
|
-0.56
+37.32%
|
-0.89
-162.43%
|
-0.34
|
| Financing Cash Flow |
|
23.27
+22.15%
|
19.05
+14226.32%
|
0.13
-99.79%
|
63.39
|
| Cash Flow From Continuing Financing Activities |
|
23.27
+22.15%
|
19.05
+14226.32%
|
0.13
-99.79%
|
63.39
|
| Net Issuance Payments Of Debt |
|
0.01
-95.36%
|
0.24
|
0.00
|
—
|
| Issuance Of Debt |
|
0.35
-16.67%
|
0.43
|
0.00
|
—
|
| Repayment Of Debt |
|
-0.34
-82.01%
|
-0.19
|
—
|
—
|
| Long Term Debt Payments |
|
-0.34
-82.01%
|
-0.19
|
—
|
—
|
| Net Long Term Debt Issuance |
|
-0.34
-82.01%
|
-0.19
|
—
|
—
|
| Short Term Debt Issuance |
|
0.35
-16.67%
|
0.43
|
0.00
|
—
|
| Net Short Term Debt Issuance |
|
0.35
-16.67%
|
0.43
|
0.00
|
—
|
| Net Common Stock Issuance |
|
23.26
+23.63%
|
18.82
|
0.00
-100.00%
|
0.02
|
| Common Stock Payments |
|
-0.03
|
—
|
—
|
—
|
| Repurchase Of Capital Stock |
|
-0.03
|
—
|
—
|
—
|
| Proceeds From Stock Option Exercised |
|
—
|
0.00
-100.00%
|
0.13
|
—
|
| Net Other Financing Charges |
|
—
|
-0.19
|
—
|
63.37
|
| Changes In Cash |
|
-2.22
+3.02%
|
-2.29
+90.64%
|
-24.45
-155.24%
|
44.27
|
| Effect Of Exchange Rate Changes |
|
0.10
+807.14%
|
-0.01
-566.67%
|
0.00
+400.00%
|
-0.00
|
| Beginning Cash Position |
|
19.69
-10.47%
|
21.99
-52.65%
|
46.44
+2032.32%
|
2.18
|
| End Cash Position |
|
17.57
-10.77%
|
19.69
-10.47%
|
21.99
-52.65%
|
46.44
|
| Free Cash Flow |
|
-25.49
-19.45%
|
-21.34
+13.19%
|
-24.59
-28.55%
|
-19.12
|
| Income Tax Paid Supplemental Data |
|
0.00
-100.00%
|
0.00
+100.00%
|
0.00
|
0.00
|
| Common Stock Issuance |
|
23.29
+23.78%
|
18.82
|
0.00
-100.00%
|
0.02
|
| Issuance Of Capital Stock |
|
23.29
+23.78%
|
18.82
|
0.00
-100.00%
|
0.02
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-03-26 View
- 10-K2026-03-26 View
- 42026-03-16 View
- 42026-02-17 View
- 42026-01-28 View
- 8-K2026-01-27 View
- 42026-01-20 View
- 42026-01-05 View
- 42026-01-05 View
- 42025-12-31 View
- 42025-12-16 View
- 42025-11-17 View
- 10-Q2025-11-13 View
- 8-K2025-11-13 View
- 42025-10-28 View
- 8-K2025-10-28 View
- 42025-10-16 View
- 8-K2025-10-03 View
- 42025-09-17 View
- 8-K2025-09-17 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|